transjugular liver biopsy
Recently Published Documents


TOTAL DOCUMENTS

201
(FIVE YEARS 36)

H-INDEX

25
(FIVE YEARS 3)

Cureus ◽  
2021 ◽  
Author(s):  
Toru Ishikawa ◽  
Erina Kodama ◽  
Takamasa Kobayashi ◽  
Motoi Azumi ◽  
Yujiro Nozawa ◽  
...  

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Bikrant Bihari Lal ◽  
Vikrant Sood ◽  
Archana Rastogi ◽  
Amar Mukund ◽  
Rajeev Khanna ◽  
...  

Author(s):  
Prabir Maji ◽  
Rohan Malik ◽  
K. S. Madhusudhan ◽  
Sanjay Sharma

Diagnostics ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 131
Author(s):  
Makoto Iijima ◽  
Takahiro Arisaka ◽  
Akira Yamamiya ◽  
Keiichi Tominaga ◽  
Kazunori Nagashima ◽  
...  

Background and study aim: Transjugular liver biopsy (TJLB) can be used in patients who are ineligible for percutaneous liver biopsy (PLB) with acute and chronic hepatic disease. This study aimed to evaluate the usefulness and safety of TJLB in patients who were not indicated for PLB. Methods: Between July 2014 and February 2019, a total of 134 patients underwent liver biopsies at our institution. Among these, PLB was performed in 110 patients and TJLB in 24 patients. A retrospective comparison of clinical results in these patients was then performed. The primary endpoints of this study were the utility and safety of TJLB in patients who were not indicated for PLB. Results: The procedural success rate was 100% in both groups. The clinical response rate and the effective tissue sampling rate were 100% in the TJLB group and 97% in the PLB group (p = 0.55). There was no difference in the number of portal fields examined retrospectively between the two groups. No serious adverse events were observed in either group. Conclusions: It is suggested that TJLB is useful because it can be safely performed in patients with poor general condition who are not indicated for PLB.


Sign in / Sign up

Export Citation Format

Share Document